CORCEPT THERAPEUTICS INC (CORT)

Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.

In the world of growth stocks, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shines as a value proposition.

Notable Monday Option Activity: GME, LULU, CORT

Corcept Therapeutics GAAP EPS of $0.28 beats by $0.02, revenue of $135.4M beats by $6.1M (NASDAQ:CORT)

Corcept Therapeutics reports Q4 2023 financial results, with GAAP EPS of $0.28 beating expectations by $0.02 and revenue of $135.4M surpassing estimates by...

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and...

Commit To Purchase Corcept Therapeutics At $18, Earn 34.5% Annualized Using Options

Corcept Appoints Roberto Vieira as President, Oncology

Noteworthy Monday Option Activity: CORT, DHT, BG

Corcept Therapeutics reports prelim Q4 rev above estimate (NASDAQ:CORT)

Corcept Therapeutics reports strong Q4 revenue, beating estimates and providing positive 2024 revenue guidance.

Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program

Canaccord Genuity sees Corcept sell-off as buying opportunity (NASDAQ:CORT)

Canaccord Genuity said Tuesday that it regards the sell-off in Corcept Therapeutics (CORT) shares as a buying opportunity, given that the company intends to app

Court Finds Corcept Therapeutics’ Patents Not Infringed

Corcept Therapeutics stock plunges after loss in patent battle with with Teva

Corcept Therapeutics (CORT) tumbles 38% in after-hours trading following a patent trial loss to Teva (TEVA) over its Cushing's syndrome drug, Korlym.